Fig. 7: The level of DNAI2 in lung cancer patients.

The level of DNAI2 in the early and late stages of lung cancer in the indicated cohorts was evaluated by IHC staining with an anti-DNAI2 antibodies A. Working model: PTEN inhibits NR2F1 expression to decrease bronchial cell hyperplasia during EGFRL858R-induced lung cancer progression but does not have this effect on alveolar cells B.